Martin Nutraceuticals Inc. in Negotiations with X Consul Group for Marketing and Distribution Rights of Its Products in Spain and Portugal.RENO, Nev. -- Martin Nutraceuticals Inc. (PINK SHEETS: MNCL MNCL Maintenance Non-Computing (Module) Load ) today announced that they have begun negotiations with X Consul Group to distribute Martin's flagship product A primary product of a company, which is typically why the company was founded and/or what made it well known. For example, MS-DOS, Windows and the Microsoft Office suite have been flagship products of Microsoft. CorelDRAW is a flagship product of Corel Corporation. Arthrizyme, in Portugal and Spain. Several opportunities exist for a successful market entry, by Martin Nutraceuticals, in Spain and Portugal with X Consul Group, the third largest distributor of dietary supplements in Spain and Portugal. With a vastly aging population stimulating the growth of dietary supplements, X Consul Group is looking to expand its product range to include products that will target specific vital segments, including arthritis and general joint pain. With a significant percentage of its general population over the age of 60, Spain and Portugal are expected to see higher incidences of degenerative disease A degenerative disease is a disease in which the function or structure of the affected tissues or organs will progressively deteriorate over time, whether due to normal bodily wear or lifestyle choices such as exercise or eating habits. and a greater susceptibility to infection. Aging consumers are adapting to a healthier lifestyle and their desire to improve the quality of life, resulting in a lucrative segment for supplement providers. "We are very excited about opening this dialogue of communication with X Consul Group. We strongly feel that the market for dietary supplements has yet to achieve a level of saturation, having the opportunity to work with a greatly respected group like X Consul, will offer us a great scope for growth and development," comments Mr. Harvey Panesar, President of Martin Nutraceuticals Inc. "Having the chance at penetrating a multi-million dollar market of Portugal and Spain and being successful at it will hopefully result in the rest of the EU (European Union European Union (EU), name given since the ratification (Nov., 1993) of the Treaty of European Union, or Maastricht Treaty, to the European Community ) opening its doors to our products." For more information, please contact Investor Relations Investor relations The process by which the corporation communicates with its investors. at (973) 351-3868 or http://www.martinnutra.com/ About Martin Nutraceuticals Inc. Martin Nutraceuticals Inc. is a company focused on providing a better health and lifestyle through natural products. Martin Nutraceuticals flagship products include Arthrizyme(TM) for general joint pain and Oxygenol(TM) for anti-oxidation and Maximum Slim(TM) for weight control. Arthrizyme(TM) is a unique blend of systemic enzymes proven to rapidly reduce inflammation in joints and muscles. Arthrizyme(TM) is not limited to anti-inflammatory effects; it also assists the body in the healing process by breaking down fibrin fibrin: see blood clotting. in joints and muscles. Arthrizyme(TM) differs from all other natural arthritis remedies and was designed to work for all types of arthritis and in all joints of the body. Arthrizyme(TM) is fast acting, usually improving symptoms within the first few days. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement This release may contain forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The risks and uncertainties that may affect the operations, performance development and results of the Company's business include but are not limited to fluctuations in financial results, availability and customer acceptance of our products and services, the impact of competitive products, services and pricing, general market trends and conditions. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion